ClinicalTrials.gg
CompletedNCT02972359Updated Nov 21, 2019Results posted

Safety of Intravenous Neridronic Acid in CRPS

A Phase 3 interventional study of Neridronic acid in Complex Regional Pain Syndrome, sponsored by Grünenthal GmbH. Completed at 46 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-21.

Sponsored by Grünenthal GmbH · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
580
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Complex Regional Pain Syndromes with a site in United States — 20 open to participants now, 22 under way, 2 of them phase 3. Complex Regional Pain Syndromes · United States.

Enrollment
Largest of 67
580 · median 30
Started
2016
with 5 others
Phase 3
12 of 88
2 open now
Registered
42nd of 88
by date
Lead sponsor
3 of 88
Grünenthal GmbH

Among the 88 studies in Complex Regional Pain Syndromes with a site in United States, this one has the largest enrollment of the 67 interventional ones that give a count, is one of 6 that started in 2016, is one of 12 in phase 3, and was the 42nd registered.

Complex Regional Pain Syndromes

206 studies on the registry are indexed under Complex Regional Pain Syndromes; 54 are open to participants now.

Browse Complex Regional Pain Syndromes studies →

Open to participants now

20 of the 88 studies in Complex Regional Pain Syndromes with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Complex Regional Pain Syndromes studies recruiting now, 17 (44%) set no upper age limit and 16 (41%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Complex Regional Pain Syndromes with a site in United States, or all of them as a file.
02

Study summary

The aim of this trial was to investigate the safety of intravenous neridronic acid in patients with complex regional pain syndrome (CRPS).

The trial was divided into 3 periods: a 60-day enrollment period, a treatment period consisting of 4 infusions over 10 days, and a follow-up period of approximately 50 weeks (with visits at Week 2, Week 6, Week 12, Week 26, Week 39, and Week 52).

Read the detailed description

At the Enrollment Visit the trial objectives, procedures, and risks were explained to the participants and the informed consent form was signed. Medical history was obtained, a physical examination was conducted, and other safety assessments were performed. Signs and symptoms of CRPS were assessed to confirm the diagnosis of CRPS according to the Budapest clinical criteria. Participants were trained to report their pain. Calcium and vitamin D supplementation were initiated to ensure sufficient vitamin D levels prior to treatment.

Participants meeting all eligibility criteria received infusions of investigational medicinal product (IMP) during visits on Day 1, Day 4, Day 7, and Day 10. Flexibility of ±1 day was allowed for Day 4, Day 7, and Day 10 whilst ensuring a minimum period of 48 hours between infusions. During the treatment period and follow-up period, pain intensity ratings were captured at the site visits in a patient reported-outcome system.

03

Conditions studied

  • Complex Regional Pain Syndrome

Keywords

  • Neridronic Acid
  • Neridronate
  • CRPS
  • RSD (reflex sympathetic dystrophy)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed.
  • Male or female participant at least 18 years of age at Visit 1.
  • A diagnosis of complex regional pain syndrome according to the clinical diagnostic criteria recommended by the International Association for the Study of Pain (IASP; "Budapest clinical criteria"), assessed at Visit 1. Signs and symptoms of CRPS must apply to an affected limb (arm or leg) and must demonstrate asymmetry with respect to the contralateral limb.
  • Ongoing moderate to severe chronic pain, including a baseline current pain intensity score of greater than or equal to 4 using an 11-point Numerical Rating Scale, referring to the CRPS-affected limb, at Visit 2 (prior to dosing).
  • In stable treatment and follow-up therapy for CRPS for at least 1 month prior to allocation to treatment (Visit 2). Participants must have failed trials of at least 2 treatments for CRPS, one of which must be a pharmacologic treatment.
  • Women of must have a negative urine beta-human chorionic gonadotropin (β-HCG) pregnancy test at Visit 1 and must be using 2 forms of medically acceptable , including at least 1 highly effective method of contraception with a low failure rate, defined as less than 1% per year (e.g., oral contraceptives or intrauterine device), and a second medically acceptable method such as use of condoms with spermicide by their male partner. A barrier method alone is not acceptable. Highly effective methods of contraception must be used for at least 1 month prior to Visit 2 and for the duration of the trial.
  • Participants must be able to communicate meaningfully, be able to differentiate with regard to location and intensity of the pain, and be able to answer the questions in the questionnaires used in this trial (assistance in filling out the questionnaires may be provided, if required due to motor or other impairment).

Exclusion criteria

Exclusion Criteria:

  • Evidence of renal impairment (estimated [eGFR] less than 60 mL/min/1.73 m2 using the 2009 Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] creatinine equation [Levey et al. 2009] or a urinary albumin creatinine ratio greater than 150 mg/g), based on central safety laboratory data obtained prior to Visit 2, or a history of chronic kidney disease. Note: a single repeat laboratory test is allowed.
  • Serum calcium or magnesium outside of the central laboratory's reference range, based on central safety laboratory data obtained prior to Visit 2 (a single repeat laboratory test is allowed); a history of hypocalcemia or a metabolic disorder anticipated to increase risk for hypocalcemia (e.g., hypoparathyroidism); concomitant use of drug(s) with known potential to cause hypocalcemia (e.g., aminoglycosides).
  • Vitamin D deficiency, defined as a 25(OH)D level less than 30 ng/mL, based on central safety laboratory data obtained prior to Visit 2 (up to 4 repeat laboratory tests are allowed). Participants with vitamin D deficiency should receive appropriate supplementation during the enrollment period. A vitamin D level of at least 30 ng/mL must be documented prior to allocation to medicinal product (IMP).
  • interval (according to Fridericia's formula; QTcF) greater than 470 ms (average of 3 [ECGs] obtained at Visit 1); serum potassium outside the central laboratory's reference range at Visit 1; clinically unstable cardiac disease, including: unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, active myocardial ischemia, or an indwelling pacemaker; evidence of complete left bundle branch block; complete atrioventricular block; history of Long QT Syndrome or a relative with this condition; or any other known risk factor for torsade de pointes.
  • Participants receiving medications with a known risk of torsades de pointes within 7 days prior to allocation. Participants receiving selective serotonin re-uptake inhibitor antidepressants (e.g., citalopram, escitalopram) or tricyclic antidepressants are eligible if the QT-interval values do not meet the exclusion criteria, the medication was started at least 1 month prior to allocation, the dose is stable, and the dose is anticipated to remain stable until at least 4 days after the last infusion of IMP.
  • Anticipated requirement for treatment with oral or intravenous bisphosphonate for another condition such as osteoporosis during the trial, or administration of denosumab (Prolia®) or other drugs affecting bone turnover or bone metabolism within 6 months prior to Visit 1.
  • History of any allergic or reaction to neridronic acid or other bisphosphonate, acetaminophen, or to vitamin D or calcium supplements.
  • Recent tooth extraction or other invasive dental procedure (within 3 months prior to Visit 1), unhealed or infected extraction site, or significant dental/periodontal disease (e.g., impacted molars, severe tooth decay, foci of infection) that may predispose to need for tooth extraction or other invasive dental procedures during the trial. Participants with indeterminate, suspicious or unreliable dental history, in the opinion of the investigator, must undergo a dental examination prior to receiving treatment.
  • Evidence of denture-related gum trauma or improperly fitting dentures causing injury.
  • Prior radiation therapy of the head or neck (within 1 year of Visit 1).
  • History of within 2 years prior to Visit 1, with the exception of basal cell carcinoma.
  • Use of nerve blocks, ketamine infusions, intravenous immunoglobulin, acupuncture, electromagnetic field treatment, or initiation/implementation of radiofrequency ablation or other sympathectomy procedures, or peripheral nerve stimulation within 6 weeks prior to Visit 2.
  • Evidence of current alcohol or drug abuse, or history of alcohol or drug abuse within 2 years of Visit 1, based on participant history and physical examination and according to the investigator's judgment.
  • Any other severe medical condition, including severe depression, or any other severe mood disorder, that in the opinion of the investigator may affect efficacy or safety assessments or may compromise the participant's safety during trial participation.
  • Women who are pregnant or breastfeeding.
  • Elevated or alanine aminotransferase greater than 2-fold , based on central safety laboratory data obtained at Visit 1, or current evidence of chronic liver disease. Safety laboratory testing may be repeated prior to Visit 2, and participants will be allowed in the trial if results of 2 consecutive tests, at least 3 days apart, are less than or equal to 2-fold upper limit of normal.
  • Participation in another investigational drug trial within 3 months prior to Visit 1 or any previous trial with neridronic acid, with the exception of participants of KF7013-01 who were assigned to placebo and did not receive neridronic acid.
  • Participant is engaged in litigation related to their disability from CRPS in which monetary gain or loss (or other compensation) may affect their objective participation in the trial.
  • Participants taking forbidden concomitant medications/therapies or not being able to follow the rules of use of concomitant treatment.
  • Participants incapable of signing the .
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
580 participants (actual)

Study arms

  • Experimental
    Neridronic acid

    Neridronic acid 100 mg administered on Day 1, Day 4, Day 7, and Day 10, resulting in a total dose of neridronic acid 400 mg.

    Drug: Neridronic acid

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Occurrence of Any Treatment Emergent Adverse Event (TEAE)

    The primary endpoint of this trial was a binary endpoint assessing whether or not a participant experienced any TEAE.

    Time frame: Day 1 to Week 52

Secondary outcomes

  1. Number of Participants With Occurrence of Permanent Discontinuation From Treatment Due to an Adverse Event

    The investigator could choose to permanently discontinue a participant from treatment if continued exposure of the participant to neridronic acid could have posed an undue risk to the participant.

    Time frame: Day 1 to Day 10

  2. Change From Baseline in the Current Pain Intensity Score

    The current Complex Regional Pain Syndrome (CRPS)-related pain intensity score was captured at each visit using an 11-point numerical rating scale where 0 = "no pain" and 10 = "pain as bad as you can imagine", a higher score indicates more pain.

    Time frame: Baseline to Week 12 and Week 26

  3. Number of Participants With Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Current Pain Intensity Score

    Participants with at least a 30 percent decrease in the current pain intensity score were considered to have responded to treatment.

    Time frame: Baseline, at Week 12 and Week 26

  4. Number of Participants With Response to Treatment, Defined as at Least 50% Decrease From Baseline in the Current Pain Intensity Score

    Participants with at least a 50 percent decrease in the current pain intensity score were considered to have responded to treatment.

    Time frame: Baseline, at Week 12 and Week 26

  5. Patient Global Impression of Change (PGIC) at Week 12

    The Patient Global Impression of Change (PGIC) is a self-reported measure of perceived change in overall condition since the start of the study. Participants selected one of seven responses ranging from "very much improved" to "very much worse". A response of "very much improved" or "much improved" is generally regarded as a clinically important improvement.

    Time frame: at Week 12

  6. Patient Global Impression of Change (PGIC) at Week 26

    The Patient Global Impression of Change (PGIC) is a self-reported measure of perceived change in overall condition since the start of the study. Participants selected one of seven responses ranging from "very much improved" to "very much worse". A response of "very much improved" or "much improved" is generally regarded as a clinically important improvement.

    Time frame: at Week 26

  7. Change in the Pain Interference Score of the Brief Pain Inventory (BPI)

    The Brief Pain Inventory (BPI) Interference Score is the mean value of 7 self-reported items in question 9 of the BPI Short Form Questionnaire. Participants rated their interference of pain with general activity, walking, work, sleep and other activities in the past 24 hours, with possible ratings from 0 (does not interfere) to 10 (completely interferes). The BPI interference Score ranges from 0 to 10, with higher values indicating greater pain interference of daily activities.

    Time frame: Baseline to Week 12 and Week 26

07

Results

Posted Nov 4, 2019
Limitations and caveats
Due to the open-label, uncontrolled nature of the trial and the concomitant use of pain medication, the effect of neridronic acid on pain intensity and the side effect profile of neridronic acid have to be interpreted with care.

Participant flow

The first participant was enrolled on 20 December 2016.

Participant flow — Overall Study
MilestoneNeridronic Acid
Started318
Completed247
Not completed71
Withdrew: Incl. criteria not met/exclusion met2
Withdrew: Lack of efficacy1
Withdrew: Adverse event4
Withdrew: Death1
Withdrew: Withdrawal by subject30
Withdrew: Protocol violation1
Withdrew: Lost to follow-up26
Withdrew: Other reasons5
Withdrew: Missing1

Outcome measures

PrimaryNumber of Participants With Occurrence of Any Treatment Emergent Adverse Event (TEAE)

The primary endpoint of this trial was a binary endpoint assessing whether or not a participant experienced any TEAE.

Time frame:
Day 1 to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Occurrence of Any Treatment Emergent Adverse Event (TEAE)
ParticipantsNeridronic Acid
Participants with TEAE277
Participants with serious TEAE27
Participants with non-serious TEAE275
Participants with unexpected TEAE267
Participants with related TEAE190
Participants with related serious TEAE3
Participants with TEAE leading to IMP discont.12
Participants with TEAE leading to trial discont.6
SecondaryNumber of Participants With Occurrence of Permanent Discontinuation From Treatment Due to an Adverse Event

The investigator could choose to permanently discontinue a participant from treatment if continued exposure of the participant to neridronic acid could have posed an undue risk to the participant.

Time frame:
Day 1 to Day 10
Reported as:
Count of participants · Participants
Number of Participants With Occurrence of Permanent Discontinuation From Treatment Due to an Adverse Event
ParticipantsNeridronic Acid
Number of Participants With Occurrence of Permanent Discontinuation From Treatment Due to an Adverse Event12
SecondaryChange From Baseline in the Current Pain Intensity Score

The current Complex Regional Pain Syndrome (CRPS)-related pain intensity score was captured at each visit using an 11-point numerical rating scale where 0 = "no pain" and 10 = "pain as bad as you can imagine", a higher score indicates more pain.

Time frame:
Baseline to Week 12 and Week 26
Reported as:
Mean · units on a scale
Change From Baseline in the Current Pain Intensity Score
units on a scaleNeridronic Acid
Baseline to Week 12-1.54 ± 2.27
Baseline to Week 26-1.57 ± 2.45
SecondaryNumber of Participants With Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Current Pain Intensity Score

Participants with at least a 30 percent decrease in the current pain intensity score were considered to have responded to treatment.

Time frame:
Baseline, at Week 12 and Week 26
Reported as:
Count of participants · Participants
Number of Participants With Response to Treatment, Defined as at Least 30% Decrease From Baseline in the Current Pain Intensity Score
ParticipantsNeridronic Acid
At least 30% pain reduction - Week 12105
At least 30% pain reduction - Week 26110
SecondaryNumber of Participants With Response to Treatment, Defined as at Least 50% Decrease From Baseline in the Current Pain Intensity Score

Participants with at least a 50 percent decrease in the current pain intensity score were considered to have responded to treatment.

Time frame:
Baseline, at Week 12 and Week 26
Reported as:
Count of participants · Participants
Number of Participants With Response to Treatment, Defined as at Least 50% Decrease From Baseline in the Current Pain Intensity Score
ParticipantsNeridronic Acid
At least 50% pain reduction - Week 1275
At least 50% pain reduction - Week 2674
SecondaryPatient Global Impression of Change (PGIC) at Week 12

The Patient Global Impression of Change (PGIC) is a self-reported measure of perceived change in overall condition since the start of the study. Participants selected one of seven responses ranging from "very much improved" to "very much worse". A response of "very much improved" or "much improved" is generally regarded as a clinically important improvement.

Time frame:
at Week 12
Reported as:
Count of participants · Participants
Patient Global Impression of Change (PGIC) at Week 12
ParticipantsNeridronic Acid
Very Much Improved31
Much Improved71
Minimally Improved98
No Change45
Minimally Worse23
Much Worse12
Very Much Worse3
Missing3
SecondaryPatient Global Impression of Change (PGIC) at Week 26

The Patient Global Impression of Change (PGIC) is a self-reported measure of perceived change in overall condition since the start of the study. Participants selected one of seven responses ranging from "very much improved" to "very much worse". A response of "very much improved" or "much improved" is generally regarded as a clinically important improvement.

Time frame:
at Week 26
Reported as:
Count of participants · Participants
Patient Global Impression of Change (PGIC) at Week 26
ParticipantsNeridronic Acid
Very Much Improved38
Much Improved58
Minimally Improved84
No Change52
Minimally Worse25
Much Worse10
Very Much Worse2
Missing4
SecondaryChange in the Pain Interference Score of the Brief Pain Inventory (BPI)

The Brief Pain Inventory (BPI) Interference Score is the mean value of 7 self-reported items in question 9 of the BPI Short Form Questionnaire. Participants rated their interference of pain with general activity, walking, work, sleep and other activities in the past 24 hours, with possible ratings from 0 (does not interfere) to 10 (completely interferes). The BPI interference Score ranges from 0 to 10, with higher values indicating greater pain interference of daily activities.

Time frame:
Baseline to Week 12 and Week 26
Reported as:
Mean · score on a scale
Change in the Pain Interference Score of the Brief Pain Inventory (BPI)
score on a scaleNeridronic Acid
Baseline to Week 12-2.2 ± 2.49
Baseline to Week 26-2.1 ± 2.64

Adverse events

Collected over Day 1 to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Neridronic Acid1/316 (0.3%)27/316 (8.5%)275/316 (87%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventNeridronic Acid
Chest painGeneral disorders2/316
PneumoniaInfections and infestations2/316
FallInjury, poisoning and procedural complications2/316
OsteoarthritisMusculoskeletal and connective tissue disorders2/316
SyncopeNervous system disorders2/316
Suicide attemptPsychiatric disorders2/316
Angina unstableCardiac disorders1/316
Myocardial infarctionCardiac disorders1/316
Stress cardiomyopathyCardiac disorders1/316
Abdominal painGastrointestinal disorders1/316
Most frequent other events
Showing 10 of 11
Most frequent other events
EventNeridronic Acid
HeadacheNervous system disorders65/316
MyalgiaMusculoskeletal and connective tissue disorders52/316
NauseaGastrointestinal disorders34/316
FatigueGeneral disorders32/316
Condition aggravatedGeneral disorders30/316
PainGeneral disorders28/316
ArthralgiaMusculoskeletal and connective tissue disorders27/316
Back painMusculoskeletal and connective tissue disorders25/316
Pain in extremityMusculoskeletal and connective tissue disorders25/316
PyrexiaGeneral disorders18/316

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Neridronic Acid
<=18 years0
Between 18 and 65 years290
>=65 years26
Age, Continuous
Age, Continuous(years)Neridronic Acid
Mean47.4 (19 to 77)
Sex: Female, Male
Sex: Female, Male(Participants)Neridronic Acid
Female237
Male79
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Neridronic Acid
Hispanic or Latino16
Not Hispanic or Latino300
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Neridronic Acid
American Indian or Alaska Native3
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American8
White297
More than one race3
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Neridronic Acid
United States308
Germany8
Body mass index (BMI)
Body mass index (BMI)(kg/m^2)Neridronic Acid
Mean28.3 ± 7.4
Baseline current pain intensity 11-point NRS
Baseline current pain intensity 11-point NRS(units on a scale)Neridronic Acid
Mean6.59 ± 1.58

1 further baseline measures are reported on the registry.

08

Study locations

46 sites
  • US017: Cactus Clinical Research, Inc.
    Phoenix, Arizona 85012, United States
  • US028: Quality of Life Medical and Research Centers LLC
    Tucson, Arizona 85712, United States
  • US045: Woodland International Research Group
    Little Rock, Arkansas 72211, United States
  • US044: Woodland Research Northwest
    Rogers, Arkansas 72758, United States
  • US012: Orange County Research Institute
    Anaheim, California 92801, United States
  • US022: Core Healthcare Group
    Cerritos, California 90703, United States
  • US033: Alliance Research Centers
    Laguna Hills, California 92653, United States
  • US027: The Helm Center for Pain Management
    Laguna Woods, California 92637, United States
  • US003: Samaritan Center for Medical Research
    Los Gatos, California 95032, United States
  • US010: Catalina Research Institute, LLC
    Montclair, California 91763, United States
  • US014: Northern California Research
    Sacramento, California 95821, United States
  • US034: Mountain View Clinical Research, Inc.
    Denver, Colorado 80209, United States
  • US032: South Lake Pain Institute
    Clermont, Florida 34711, United States
  • US001: Sunrise Research Institute, Inc
    Miami, Florida 33130, United States
  • US046: AMPM Research Clinic
    Miami, Florida 33169, United States
  • US035: Compass Research
    Orlando, Florida 32806, United States
  • US031: Gold Coast Research, LLC
    Plantation, Florida 33317, United States
  • US011: Clinical Research of West Florida, Inc.
    Tampa, Florida 33603, United States
  • US040: Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • US026: Better Health Clinical Research Inc.
    Newnan, Georgia 30265, United States
  • US004: Northwestern University - Feinberg School of Medicine - Rehabilitation Institute of Chicago (RIC)
    Chicago, Illinois 60611, United States
  • US036: University Anesthesiologists, S.C.
    Chicago, Illinois 60612, United States
  • US029: Great Lakes Clinical Trials LLC
    Chicago, Illinois 60640, United States
  • US005: International Clinical Research Institute
    Overland Park, Kansas 66210, United States
  • US037: St. Louis Clinical Trials, LC
    Saint Louis, Missouri 63141, United States
  • US051: Creighton University, Osteoporosis Research Center
    Omaha, Nebraska 68122, United States
  • US002: Princeton Medical Institute
    Princeton, New Jersey 08540, United States
  • US049: Premier Pain Centers, LLC
    Shrewsbury, New Jersey 07702, United States
  • US048: Albany Medical College
    Albany, New York 12208, United States
  • US043: Translational Pain Research, University of Rochester
    Rochester, New York 14618, United States
  • US009: The Center for Clinical Research, LLC
    Winston-Salem, North Carolina 27103, United States
  • US016: North Star Medical Research, LLC
    Middleburg Heights, Ohio 44130, United States
  • US007: Medical Research International
    Oklahoma City, Oklahoma 73109-4520, United States
  • US006: Abington Neurological Associates, LTD.
    Willow Grove, Pennsylvania 19090, United States
  • US020: Clinical Trials of South Carolina
    Charleston, South Carolina 29406, United States
  • US038: Vanderbilt University Medical Center
    Nashville, Tennessee 37212-1050, United States
  • US019: Austin Center for Clinical Research
    Austin, Texas 78758, United States
  • US008: Pioneer Research Solutions
    Houston, Texas 77099, United States
  • US023: Axios Research, LLC
    Salt Lake City, Utah 84106, United States
  • US018: Washington Center for Pain Management
    Bellevue, Washington 98004, United States
  • US015: Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • US013: Swedish Pain Services/ Research Institute
    Seattle, Washington 98122, United States
  • DE001: Klinische Forschung Hannover-Mitte GmbH
    Hannover, 30159, Germany
  • DE004: Schmerzambulanz Medizinishe Hochschule Hannover
    Hannover, 30625, Germany
  • DE006: AmBeNet GmbH
    Leipzig, 04107, Germany
  • DE002: Schmerztagesklinik der Anästhesiologie Universitätsklinikum Würzburg
    Würzburg, 97080, Germany
09

References and documents

Publications

  • Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006. Erratum In: Ann Intern Med. 2011 Sep 20;155(6):408. PubMed 19414839 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Information available on the Grünenthal Web Site

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Data sharing details ↗ · www.grunenthal.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Jan 2019, 24 months.

Results were first posted in Nov 2019, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2016
First posted
Nov 23, 2016
StartActual
Dec 20, 2016
Primary completionActual
Jan 9, 2019
CompletionActual
Jan 9, 2019
Results first posted
Nov 4, 2019
Last update
Nov 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02972359
Lead sponsor
Grünenthal GmbH
Responsible party
Sponsor
First posted
Nov 23, 2016
Start date
Dec 20, 2016
Primary completion
Jan 9, 2019
Completion
Jan 9, 2019
Results posted
Nov 4, 2019
Last update
Nov 21, 2019

Study contacts

Study Director
study director · Grünenthal GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Neridronic acid

Start the discussion